Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05522868 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05522868 · ClinicalTrials.gov record · last posted 2025-11-20

SB17170 Phase 1 Clinical Trial in Solid Tumors

Name: SB17170 Phase 1 Clinical Trial in Solid Tumors — clinical trial record (NCT05522868)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorSPARK Biopharma

Started2022-10-17

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

Phase 1 Open-label, multicenter, dose escalation, dose expansion study

Amendment record 6 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 6 times since 2022-08-28; most recent amendment 2025-11-17. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-11-17

Status change Active, Not Recruiting→Recruitingv6

2024-12-15

Status change Recruiting→Active, Not Recruitingv3

2022-10-26

Status change Not Yet Recruiting→Recruitingv1

Trial Details

NCT Number	NCT05522868
Lead Sponsor	SPARK Biopharma
Conditions	Solid Tumor
Enrollment	50 participants
Start Date	2022-10-17
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-11-20